CPT code 0070U designates a proprietary genetic test — the CYP2D6 Common Variants and Copy Number assay developed by the Mayo Clinic Laboratory — used to detect variants and copy number changes in the CYP2D6 gene that influence drug metabolism. As a PLA code, 0070U applies to this single manufacturer/laboratory-specific assay. Nationally, pharmacogenomic testing for CYP2D6 has implications for medication safety and efficacy across oncology, pain management, and psychiatry because CYP2D6 metabolizes widely used drugs such as tamoxifen, codeine, and tramadol.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines payer coverage considerations and benchmarking where available, and summarizes the clinical context for ordering this pharmacogenomic assay.

Readers will learn the clinical purpose and testing scope of CPT code 0070U, typical sites of service and service type, and which major national payers are relevant to coverage discussions. The report also identifies where input data was unavailable and highlights areas for follow-up, including payer-specific coverage policies and coding relationships. Data not available in the input includes detailed payer policy language, associated taxonomies, ICD-10 diagnosis codes, and related CPT/HCPCS crosswalks.